Parker Sareeta R S, Bradley Bridget
Department of Dermatology, Emory University, Atlanta, GA, USA.
Dermatol Nurs. 2006 Dec;18(6):566-70, 573-5.
The cause of mycosis fungoides is unknown and, with the possible exception of very early stage disease, no cure is available. Fortunately, patients with MF have a number of therapeutic options and partial and complete remissions are achievable. Because it is not curable, the burden for patients with this disease involves the need for lifelong therapy and monitoring, and meticulous skin care. Despite its indolent nature in most individuals, the disease has a tremendous psychological impact, not only because of the visible nature of the skin lesions, but also due to the rarity of the disease and its chronicity. Knowledge of this disease, therapeutic options, and expectations of therapy will enhance care of patients afflicted with mycosis fungoides. Ongoing research provides hope that in the future, therapy to induce long-lasting remission, or even cure, will become available. Since the submission of this manuscript, vorinostat (Zolinza), an orally administered histone inhibitor, has been FDA approved for treating skin manifestations in patients with CTCL.
蕈样肉芽肿的病因尚不清楚，除了极早期疾病外，目前尚无治愈方法。幸运的是，蕈样肉芽肿患者有多种治疗选择，部分缓解和完全缓解是可以实现的。由于无法治愈，这种疾病给患者带来的负担包括需要终身治疗和监测，以及精心的皮肤护理。尽管在大多数人身上其病程较为缓慢，但该疾病具有巨大的心理影响，不仅因为皮肤病变可见，还由于该疾病的罕见性及其慢性病程。了解这种疾病、治疗选择以及对治疗的期望将改善对蕈样肉芽肿患者的护理。正在进行的研究带来了希望，即在未来，诱导长期缓解甚至治愈的治疗方法将会出现。自本手稿提交以来，口服组蛋白抑制剂伏立诺他（Zolinza）已获美国食品药品监督管理局批准用于治疗皮肤T细胞淋巴瘤患者的皮肤表现。
